Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies, has entered into a lease agreement to enable in-house cell-therapy manufacturing to supply clinical trials. The additional 27,000 square feet will be located in the company's current headquarters building adjacent to the Texas Medical Center in Houston.

Bellicum is focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The company is using its proprietary Chemical Induction of Dimerization (CID), technology platform to engineer and control components of the immune system in real time. Bellicum is developing product candidates in some of the most various areas of cellular immunotherapy, including hematopoietic stem cell transplantation, CAR (chimeric antigen receptors) T cell therapy, and dendritic cell vaccines.

Source: Bellicum Pharmaceuticals